Sirtris unveils promising, novel SIRT1 activators for treating disease...(iabetes and insulin resistance (Zucker f...)

Date:11/28/2007

iabetes and insulin resistance (Zucker fa/fa rats), these SIRT1 activators improved whole-body glucose homeostasis and insulin sensitivity in adipose tissue, skeletal muscle and liver. These rodent models of diabetes are considered highly predictive of efficacy in humans.

The World Health Organization (WHO) indicates that Type 2 Diabetes (formerly called adult-onset diabetes) results from the bodys ineffective use of insulin. Type 2 Diabetes accounts for 90% of diabetes around the world, and is largely the result of excess body weight and physical inactivity. WHO estimates that more than 180 million people worldwide have diabetes and this number is likely to more than double by 2030. Furthermore, WHO projects that deaths due to diabetes will increase by more than 50% in the next 10 years. Activating SIRT 1 appears to mimic the beneficial effects of calorie restriction on mitochondrial and metabolic function in mammals in vivo and holds promise for treating diseases of aging, such as Type 2 Diabetes.

"We are very excited about these findings, which expand on the breakthrough data published in 2006 in the journals Nature and Cell, which demonstrated that SIRT1 activators mimic calorie restriction and extend lifespan. For the first time, the article published today shows that the novel drug candidates we have identified are the most potent SIRT1 activators ever to be published -- 1,000 times more potent than resveratrol -- and can potentially unlock a whole new approach to treating Type 2 Diabetes," stated Jill C. Milne, Ph.D., lead author of the Nature study and Senior Director of Biology at Sirtris.

Westphal added, Now we have an even more potent way of eliciting the beneficial effects observed in earlier research with resveratrol. The NCEs characterized in this study are significantly more potent than and structurally unrelated to resveratrol. These findings highlight the tremendous potential of our NCE program to treat diseases of ag
'/>"/>

Contact: Sheryl Seapy sheryl@purecommunicationsinc.com 949-608-0841 Pure Communications Inc. Source:Eurekalert

0 GOOD

Page: 1 2 3
Related biology news :

1. EC unveils new EU maritime policy
2. Tumor genome analysis unveils new insights into lung cancer
3. MGH researchers describe new way to identify, evolve novel enzymes
4. Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
5. Novel 3-D cell culture model shows selective tumor uptake of nanoparticles
6. IdentiPHI Re Launches SAFmodule Software to Secure Novell(R) Networks
7. IdentiPHI Re Launches SAFmodule Software to Secure Novell(R) Networks
8. 454 Sequencing: Science paper describes a novel, highly efficient method of sequencing ancient DNA
9. Scientists discover novel way to remove iron from ferritin
10. Identification of a novel class of (not-so) small RNAs
11. A novel way found to prevent protein plaques implicated in Alzheimers